Industry Research Reports
Home > Reports > Service & Software > Global Gene Cell Therapy CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Gene Cell Therapy CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Industry: Service & Software
Published Date: 2026-03-31
Pages: 108 Pages
Report ld: 6391375
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Gene Cell Therapy CDMO Market Size(US$)
CAGR 2026-2032
7.8%
Market Size,2032
USD 4,201
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 2,676 million
Market Forecast in 2032(Value)
US$ 4,201 million
CAGR
7.8%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Gene Cell Therapy CDMO market size was US$ 2500 million in 2025 and is forecast to reach a readjusted size of US$ 4201 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Gene Cell Therapy CDMO provides end-to-end customized R&D and manufacturing services for advanced therapies such as gene therapy and cell therapy, from process development to production scale-up. Their core strength lies in addressing the extreme complexity of using live cells or viral vectors as "drugs," encompassing vector design and construction, cell collection and modification, process development and optimization, rigorous quality control and release testing, and clinical- and commercial-grade aseptic manufacturing. This field has extremely high barriers to entry, requiring companies to possess cutting-edge biological technologies, GMP-compliant closed-loop automated production systems, and the expertise to meet stringent global regulations. They are indispensable industrialization partners for pharmaceutical companies to bring cutting-edge therapies from the laboratory to market.
Gene Cell Therapy CDMO has a highly complex cost structure, primarily including cutting-edge R&D and highly skilled human resources costs, customized GMP facilities and expensive one-time production consumables, as well as stringent quality control and testing fees. Their gross profit margins range widely (typically 30%-60% or higher), depending mainly on the uniqueness of the technology platform, process efficiency, and capacity utilization. Early highly personalized therapies face significant cost pressures due to limited scale, while mature, large-scale platform-based manufacturing (such as allogeneic therapies and viral vectors) can achieve higher profitability through standardization and capacity expansion.
The global landscape of Gene Cell Therapy CDMO is characterized by "technology leadership, regional concentration, and multi-point breakthroughs." North America remains the absolute innovation center and largest source of demand globally, boasting the most mature capital markets, top biotech companies, and leading CDMO firms, dominating technology and standard development. Europe follows closely behind, possessing strong capabilities in specific technological routes and clinical translation thanks to its deep research foundation and rigorous regulatory system. The Asia-Pacific region, especially China, is becoming the fastest-growing market globally, driven by strong policy support, the rise of domestic innovative pharmaceutical companies, and huge clinical demand. It is rapidly moving from early technology imports to independent innovation and internationalization, with South Korea and Japan also actively expanding their presence. Currently, supply chain stability, geopolitical factors, and the need for proximity to clinical centers are driving the global production capacity layout towards regionalization and diversification.
The global Gene Cell Therapy CDMO market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
MARKET SEGMENTATION
By Company
- Catalent
- Lonza
- Charles River
- Oxford Biomedica
- Novartis
- OBiO
- GenScript
- Pharmaron
- Porton
- Resilience
- SK Pharmteco
- Forge Biologics
- Andelyn Biosciences
- Roslin CT
- eXmoor Pharma
- Advanced Therapies
- Catalent Biologics
- Patheon Pharma Services
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Immune Cells
- Stem Cell
- Viral Vector
- Plasmid DNA
Segment by Application
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutions
- Hospital
- Others
Segment by Category
- Early-stage CDMO and preclinical CDMO
- Clinical-stage CDMO
- Commercial-stage CDMO
Segment by Division
- Centralized Factory Model
- Distributed Regional Production Model
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Gene Cell Therapy CDMO value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 Immune Cells
1.2.3 Stem Cell
1.2.4 Viral Vector
1.2.5 Plasmid DNA
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research and Academic Institutions
1.3.4 Hospital
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Cell Therapy CDMO Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Gene Cell Therapy CDMO Market Share by Revenue, by Region (2021-2026)
2.4 Global Gene Cell Therapy CDMO Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Gene Cell Therapy CDMO Market Size and Prospective (2021-2032)
2.5.2 Europe Gene Cell Therapy CDMO Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific Gene Cell Therapy CDMO Market Size and Prospective (2021-2032)
2.5.4 Latin America Gene Cell Therapy CDMO Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa Gene Cell Therapy CDMO Market Size and Prospective (2021-2032)
3 Breakdown Data by Type
3.1 Global Gene Cell Therapy CDMO Historical Market Size by Type (2021-2026)
3.2 Global Gene Cell Therapy CDMO Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Gene Cell Therapy CDMO
4 Breakdown Data by Application
4.1 Global Gene Cell Therapy CDMO Historical Market Size by Application (2021-2026)
4.2 Global Gene Cell Therapy CDMO Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Gene Cell Therapy CDMO Applications
5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Gene Cell Therapy CDMO Players by Revenue (2021-2026)
5.1.2 Global Gene Cell Therapy CDMO Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Gene Cell Therapy CDMO Revenue
5.4 Global Gene Cell Therapy CDMO Market Concentration Analysis
5.4.1 Global Gene Cell Therapy CDMO Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Gene Cell Therapy CDMO Revenue in 2025
5.5 Global Key Players of Gene Cell Therapy CDMO Head Offices and Areas Served
5.6 Global Key Players of Gene Cell Therapy CDMO, Product and Application
5.7 Global Key Players of Gene Cell Therapy CDMO, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Gene Cell Therapy CDMO Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Gene Cell Therapy CDMO Market Size by Type (2021-2026)
6.1.2.2 North America Gene Cell Therapy CDMO Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Gene Cell Therapy CDMO Market Size by Application (2021-2026)
6.1.3.2 North America Gene Cell Therapy CDMO Market Share by Application (2021-2026)
6.1.4 North America Gene Cell Therapy CDMO Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Gene Cell Therapy CDMO Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Gene Cell Therapy CDMO Market Size by Type (2021-2026)
6.2.2.2 Europe Gene Cell Therapy CDMO Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Gene Cell Therapy CDMO Market Size by Application (2021-2026)
6.2.3.2 Europe Gene Cell Therapy CDMO Market Share by Application (2021-2026)
6.2.4 Europe Gene Cell Therapy CDMO Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific Gene Cell Therapy CDMO Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Gene Cell Therapy CDMO Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific Gene Cell Therapy CDMO Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Gene Cell Therapy CDMO Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific Gene Cell Therapy CDMO Market Share by Application (2021-2026)
6.3.4 Asia-Pacific Gene Cell Therapy CDMO Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America Gene Cell Therapy CDMO Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Gene Cell Therapy CDMO Market Size by Type (2021-2026)
6.4.2.2 Latin America Gene Cell Therapy CDMO Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Gene Cell Therapy CDMO Market Size by Application (2021-2026)
6.4.3.2 Latin America Gene Cell Therapy CDMO Market Share by Application (2021-2026)
6.4.4 Latin America Gene Cell Therapy CDMO Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa Gene Cell Therapy CDMO Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Gene Cell Therapy CDMO Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa Gene Cell Therapy CDMO Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Gene Cell Therapy CDMO Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa Gene Cell Therapy CDMO Market Share by Application (2021-2026)
6.5.4 Middle East & Africa Gene Cell Therapy CDMO Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities
7 Key Player Profiles
7.1 Catalent
7.1.1 Catalent Company Details
7.1.2 Catalent Business Overview
7.1.3 Catalent Gene Cell Therapy CDMO Introduction
7.1.4 Catalent Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.1.5 Catalent Recent Development
7.2 Lonza
7.2.1 Lonza Company Details
7.2.2 Lonza Business Overview
7.2.3 Lonza Gene Cell Therapy CDMO Introduction
7.2.4 Lonza Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.2.5 Lonza Recent Development
7.3 Charles River
7.3.1 Charles River Company Details
7.3.2 Charles River Business Overview
7.3.3 Charles River Gene Cell Therapy CDMO Introduction
7.3.4 Charles River Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.3.5 Charles River Recent Development
7.4 Oxford Biomedica
7.4.1 Oxford Biomedica Company Details
7.4.2 Oxford Biomedica Business Overview
7.4.3 Oxford Biomedica Gene Cell Therapy CDMO Introduction
7.4.4 Oxford Biomedica Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.4.5 Oxford Biomedica Recent Development
7.5 Novartis
7.5.1 Novartis Company Details
7.5.2 Novartis Business Overview
7.5.3 Novartis Gene Cell Therapy CDMO Introduction
7.5.4 Novartis Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.5.5 Novartis Recent Development
7.6 OBiO
7.6.1 OBiO Company Details
7.6.2 OBiO Business Overview
7.6.3 OBiO Gene Cell Therapy CDMO Introduction
7.6.4 OBiO Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.6.5 OBiO Recent Development
7.7 GenScript
7.7.1 GenScript Company Details
7.7.2 GenScript Business Overview
7.7.3 GenScript Gene Cell Therapy CDMO Introduction
7.7.4 GenScript Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.7.5 GenScript Recent Development
7.8 Pharmaron
7.8.1 Pharmaron Company Details
7.8.2 Pharmaron Business Overview
7.8.3 Pharmaron Gene Cell Therapy CDMO Introduction
7.8.4 Pharmaron Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.8.5 Pharmaron Recent Development
7.9 Porton
7.9.1 Porton Company Details
7.9.2 Porton Business Overview
7.9.3 Porton Gene Cell Therapy CDMO Introduction
7.9.4 Porton Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.9.5 Porton Recent Development
7.10 Resilience
7.10.1 Resilience Company Details
7.10.2 Resilience Business Overview
7.10.3 Resilience Gene Cell Therapy CDMO Introduction
7.10.4 Resilience Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.10.5 Resilience Recent Development
7.11 SK Pharmteco
7.11.1 SK Pharmteco Company Details
7.11.2 SK Pharmteco Business Overview
7.11.3 SK Pharmteco Gene Cell Therapy CDMO Introduction
7.11.4 SK Pharmteco Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.11.5 SK Pharmteco Recent Development
7.12 Forge Biologics
7.12.1 Forge Biologics Company Details
7.12.2 Forge Biologics Business Overview
7.12.3 Forge Biologics Gene Cell Therapy CDMO Introduction
7.12.4 Forge Biologics Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.12.5 Forge Biologics Recent Development
7.13 Andelyn Biosciences
7.13.1 Andelyn Biosciences Company Details
7.13.2 Andelyn Biosciences Business Overview
7.13.3 Andelyn Biosciences Gene Cell Therapy CDMO Introduction
7.13.4 Andelyn Biosciences Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.13.5 Andelyn Biosciences Recent Development
7.14 Roslin CT
7.14.1 Roslin CT Company Details
7.14.2 Roslin CT Business Overview
7.14.3 Roslin CT Gene Cell Therapy CDMO Introduction
7.14.4 Roslin CT Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.14.5 Roslin CT Recent Development
7.15 eXmoor Pharma
7.15.1 eXmoor Pharma Company Details
7.15.2 eXmoor Pharma Business Overview
7.15.3 eXmoor Pharma Gene Cell Therapy CDMO Introduction
7.15.4 eXmoor Pharma Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.15.5 eXmoor Pharma Recent Development
7.16 Advanced Therapies
7.16.1 Advanced Therapies Company Details
7.16.2 Advanced Therapies Business Overview
7.16.3 Advanced Therapies Gene Cell Therapy CDMO Introduction
7.16.4 Advanced Therapies Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.16.5 Advanced Therapies Recent Development
7.17 Catalent Biologics
7.17.1 Catalent Biologics Company Details
7.17.2 Catalent Biologics Business Overview
7.17.3 Catalent Biologics Gene Cell Therapy CDMO Introduction
7.17.4 Catalent Biologics Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.17.5 Catalent Biologics Recent Development
7.18 Patheon Pharma Services
7.18.1 Patheon Pharma Services Company Details
7.18.2 Patheon Pharma Services Business Overview
7.18.3 Patheon Pharma Services Gene Cell Therapy CDMO Introduction
7.18.4 Patheon Pharma Services Revenue in Gene Cell Therapy CDMO Business (2021-2026)
7.18.5 Patheon Pharma Services Recent Development
8 Gene Cell Therapy CDMO Market Dynamics
8.1 Gene Cell Therapy CDMO Industry Trends
8.2 Gene Cell Therapy CDMO Market Drivers
8.3 Gene Cell Therapy CDMO Market Challenges
8.4 Gene Cell Therapy CDMO Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Gene Cell Therapy CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Gene Cell Therapy CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market Gene Cell Therapy CDMO Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global Gene Cell Therapy CDMO Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global Gene Cell Therapy CDMO Revenue Share by Region (2021-2026)
Table 6. Global Gene Cell Therapy CDMO Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global Gene Cell Therapy CDMO Revenue Share Forecast by Region (2027-2032)
Table 8. Global Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global Gene Cell Therapy CDMO Market Share by Revenue, by Type (2021-2026)
Table 10. Global Gene Cell Therapy CDMO Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global Gene Cell Therapy CDMO Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global Gene Cell Therapy CDMO Market Share by Revenue, by Application (2021-2026)
Table 15. Global Gene Cell Therapy CDMO Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global Gene Cell Therapy CDMO Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in Gene Cell Therapy CDMO Applications
Table 18. Global Gene Cell Therapy CDMO Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global Gene Cell Therapy CDMO Market Share by Players (2021-2026)
Table 20. Global Top Gene Cell Therapy CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Cell Therapy CDMO as of 2025)
Table 21. Ranking of Global Top Gene Cell Therapy CDMO Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Gene Cell Therapy CDMO Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of Gene Cell Therapy CDMO, Headquarters and Area Served
Table 24. Global Key Players of Gene Cell Therapy CDMO, Product and Application
Table 25. Global Key Players of Gene Cell Therapy CDMO, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Gene Cell Therapy CDMO Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America Gene Cell Therapy CDMO Market Share by Revenue, by Company (2021-2026)
Table 29. North America Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe Gene Cell Therapy CDMO Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe Gene Cell Therapy CDMO Market Share by Revenue, by Company (2021-2026)
Table 33. Europe Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific Gene Cell Therapy CDMO Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific Gene Cell Therapy CDMO Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America Gene Cell Therapy CDMO Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America Gene Cell Therapy CDMO Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa Gene Cell Therapy CDMO Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Gene Cell Therapy CDMO Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 47. Catalent Company Details
Table 48. Catalent Business Overview
Table 49. Catalent Gene Cell Therapy CDMO Product
Table 50. Catalent Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 51. Catalent Recent Development
Table 52. Lonza Company Details
Table 53. Lonza Business Overview
Table 54. Lonza Gene Cell Therapy CDMO Product
Table 55. Lonza Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 56. Lonza Recent Development
Table 57. Charles River Company Details
Table 58. Charles River Business Overview
Table 59. Charles River Gene Cell Therapy CDMO Product
Table 60. Charles River Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 61. Charles River Recent Development
Table 62. Oxford Biomedica Company Details
Table 63. Oxford Biomedica Business Overview
Table 64. Oxford Biomedica Gene Cell Therapy CDMO Product
Table 65. Oxford Biomedica Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 66. Oxford Biomedica Recent Development
Table 67. Novartis Company Details
Table 68. Novartis Business Overview
Table 69. Novartis Gene Cell Therapy CDMO Product
Table 70. Novartis Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 71. Novartis Recent Development
Table 72. OBiO Company Details
Table 73. OBiO Business Overview
Table 74. OBiO Gene Cell Therapy CDMO Product
Table 75. OBiO Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 76. OBiO Recent Development
Table 77. GenScript Company Details
Table 78. GenScript Business Overview
Table 79. GenScript Gene Cell Therapy CDMO Product
Table 80. GenScript Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 81. GenScript Recent Development
Table 82. Pharmaron Company Details
Table 83. Pharmaron Business Overview
Table 84. Pharmaron Gene Cell Therapy CDMO Product
Table 85. Pharmaron Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 86. Pharmaron Recent Development
Table 87. Porton Company Details
Table 88. Porton Business Overview
Table 89. Porton Gene Cell Therapy CDMO Product
Table 90. Porton Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 91. Porton Recent Development
Table 92. Resilience Company Details
Table 93. Resilience Business Overview
Table 94. Resilience Gene Cell Therapy CDMO Product
Table 95. Resilience Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 96. Resilience Recent Development
Table 97. SK Pharmteco Company Details
Table 98. SK Pharmteco Business Overview
Table 99. SK Pharmteco Gene Cell Therapy CDMO Product
Table 100. SK Pharmteco Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 101. SK Pharmteco Recent Development
Table 102. Forge Biologics Company Details
Table 103. Forge Biologics Business Overview
Table 104. Forge Biologics Gene Cell Therapy CDMO Product
Table 105. Forge Biologics Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 106. Forge Biologics Recent Development
Table 107. Andelyn Biosciences Company Details
Table 108. Andelyn Biosciences Business Overview
Table 109. Andelyn Biosciences Gene Cell Therapy CDMO Product
Table 110. Andelyn Biosciences Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 111. Andelyn Biosciences Recent Development
Table 112. Roslin CT Company Details
Table 113. Roslin CT Business Overview
Table 114. Roslin CT Gene Cell Therapy CDMO Product
Table 115. Roslin CT Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 116. Roslin CT Recent Development
Table 117. eXmoor Pharma Company Details
Table 118. eXmoor Pharma Business Overview
Table 119. eXmoor Pharma Gene Cell Therapy CDMO Product
Table 120. eXmoor Pharma Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 121. eXmoor Pharma Recent Development
Table 122. Advanced Therapies Company Details
Table 123. Advanced Therapies Business Overview
Table 124. Advanced Therapies Gene Cell Therapy CDMO Product
Table 125. Advanced Therapies Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 126. Advanced Therapies Recent Development
Table 127. Catalent Biologics Company Details
Table 128. Catalent Biologics Business Overview
Table 129. Catalent Biologics Gene Cell Therapy CDMO Product
Table 130. Catalent Biologics Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 131. Catalent Biologics Recent Development
Table 132. Patheon Pharma Services Company Details
Table 133. Patheon Pharma Services Business Overview
Table 134. Patheon Pharma Services Gene Cell Therapy CDMO Product
Table 135. Patheon Pharma Services Revenue in Gene Cell Therapy CDMO Business (2021-2026) & (US$ Million)
Table 136. Patheon Pharma Services Recent Development
Table 137. Gene Cell Therapy CDMO Market Trends
Table 138. Gene Cell Therapy CDMO Market Drivers
Table 139. Gene Cell Therapy CDMO Market Challenges
Table 140. Gene Cell Therapy CDMO Market Restraints
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Gene Cell Therapy CDMO Product Picture
Figure 2. Global Gene Cell Therapy CDMO Market Share by Type: 2025 vs 2032
Figure 3. Immune Cells Features
Figure 4. Stem Cell Features
Figure 5. Viral Vector Features
Figure 6. Plasmid DNA Features
Figure 7. Global Gene Cell Therapy CDMO Market Share by Application: 2025 vs 2032
Figure 8. Pharmaceutical and Biotechnology Companies
Figure 9. Research and Academic Institutions
Figure 10. Hospital
Figure 11. Others
Figure 12. Gene Cell Therapy CDMO Report Years Considered
Figure 13. Global Gene Cell Therapy CDMO Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 14. Global Gene Cell Therapy CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Gene Cell Therapy CDMO Market Share by Revenue, by Region: 2021 vs 2025
Figure 16. North America Gene Cell Therapy CDMO Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. Europe Gene Cell Therapy CDMO Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. Asia-Pacific Gene Cell Therapy CDMO Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Latin America Gene Cell Therapy CDMO Revenue (US$ Million) Growth Rate (2021-2032)
Figure 20. Middle East & Africa Gene Cell Therapy CDMO Revenue (US$ Million) Growth Rate (2021-2032)
Figure 21. Global Gene Cell Therapy CDMO Market Share by Players in 2025
Figure 22. Global Top Gene Cell Therapy CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Cell Therapy CDMO as of 2025)
Figure 23. The Top 10 and 5 Players Market Share by Gene Cell Therapy CDMO Revenue in 2025
Figure 24. North America Gene Cell Therapy CDMO Market Share by Type (2021-2026)
Figure 25. North America Gene Cell Therapy CDMO Market Share by Application (2021-2026)
Figure 26. Europe Gene Cell Therapy CDMO Market Share by Type (2021-2026)
Figure 27. Europe Gene Cell Therapy CDMO Market Share by Application (2021-2026)
Figure 28. Asia-Pacific Gene Cell Therapy CDMO Market Share by Type (2021-2026)
Figure 29. Asia-Pacific Gene Cell Therapy CDMO Market Share by Application (2021-2026)
Figure 30. Latin America Gene Cell Therapy CDMO Market Share by Type (2021-2026)
Figure 31. Latin America Gene Cell Therapy CDMO Market Share by Application (2021-2026)
Figure 32. Middle East & Africa Gene Cell Therapy CDMO Market Share by Type (2021-2026)
Figure 33. Middle East & Africa Gene Cell Therapy CDMO Market Share by Application (2021-2026)
Figure 34. Catalent Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 35. Lonza Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 36. Charles River Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 37. Oxford Biomedica Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 38. Novartis Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 39. OBiO Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 40. GenScript Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 41. Pharmaron Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 42. Porton Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 43. Resilience Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 44. SK Pharmteco Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 45. Forge Biologics Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 46. Andelyn Biosciences Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 47. Roslin CT Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 48. eXmoor Pharma Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 49. Advanced Therapies Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 50. Catalent Biologics Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 51. Patheon Pharma Services Revenue Growth Rate in Gene Cell Therapy CDMO Business (2021-2026)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What is the annual compound growth rate of the global Gene Cell Therapy CDMO market size from 2026 to 2032?
The annual compound growth rate of the global Gene Cell Therapy CDMO market is 7.8% 2026 to 2032.
Which region is expected to have the highest market share?
What was the global market size of Gene Cell Therapy CDMO in 2032?
Which companies rank high in the global Gene Cell Therapy CDMO market?
What was the global market size of Gene Cell Therapy CDMO in 2026?
Related Reports
Global Gene Cell Therapy CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Gene Cell Therapy CDMO market is projected to grow from US$ 2500 million in 2025 to US$ 4201 million by 2032, at a CAGR of 7.8% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-31
Pages: 149
USD 4900.00
(Single User License)
Gene Cell Therapy CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ 2500 million in 2025 and is projected to reach US$ 4201 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-19
Pages: 126
USD 3950.00
(Single User License)
Global Gene Cell Therapy CDMO Market Research Report 2026
The global Gene Cell Therapy CDMO market was valued at US$ 2500 million in 2025 and is anticipated to reach US$ 4201 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-15
Pages: 128
USD 2900.00
(Single User License)
Gene Cell Therapy CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ 2320 million in 2024 and is forecast to a readjusted size of US$ 3925 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-12-12
Pages: 123
USD 3950.00
(Single User License)
Global Gene Cell Therapy CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Gene Cell Therapy CDMO market size was US$ 2320 million in 2024 and is forecast to a readjusted size of US$ 3925 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-12-12
Pages: 105
USD 4250.00
(Single User License)
Global Gene Cell Therapy CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Gene Cell Therapy CDMO market is projected to grow from US$ 2320 million in 2024 to US$ 3925 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-12-12
Pages: 159
USD 4900.00
(Single User License)
Global Gene Cell Therapy CDMO Market Research Report 2025
The global market for Gene Cell Therapy CDMO was valued at US$ 2320 million in the year 2024 and is projected to reach a revised size of US$ 3925 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published Date: 2025-12-12
Pages: 121
USD 2900.00
(Single User License)
Gene Cell Therapy CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-03-11
Pages: 112
USD 3950.00
(Single User License)
Global Gene Cell Therapy CDMO Market Research Report 2024
The global Gene Cell Therapy CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
Published Date: 2024-04-28
Pages: 89
USD 2900.00
(Single User License)
Gene Cell Therapy CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of %during the forecast period 2024-2030.
Published Date: 2024-04-28
Pages: 109
USD 3950.00
(Single User License)
Global Gene Cell Therapy CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Gene Cell Therapy CDMO market is projected to grow from US$ 2500 million in 2025 to US$ 4201 million by 2032, at a CAGR of 7.8% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-31
Pages: 149
USD 4900.00 (Single User License)Gene Cell Therapy CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ 2500 million in 2025 and is projected to reach US$ 4201 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-19
Pages: 126
USD 3950.00 (Single User License)Global Gene Cell Therapy CDMO Market Research Report 2026
The global Gene Cell Therapy CDMO market was valued at US$ 2500 million in 2025 and is anticipated to reach US$ 4201 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-15
Pages: 128
USD 2900.00 (Single User License)Gene Cell Therapy CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ 2320 million in 2024 and is forecast to a readjusted size of US$ 3925 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-12-12
Pages: 123
USD 3950.00 (Single User License)Global Gene Cell Therapy CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Gene Cell Therapy CDMO market size was US$ 2320 million in 2024 and is forecast to a readjusted size of US$ 3925 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-12-12
Pages: 105
USD 4250.00 (Single User License)Global Gene Cell Therapy CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Gene Cell Therapy CDMO market is projected to grow from US$ 2320 million in 2024 to US$ 3925 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-12-12
Pages: 159
USD 4900.00 (Single User License)Global Gene Cell Therapy CDMO Market Research Report 2025
The global market for Gene Cell Therapy CDMO was valued at US$ 2320 million in the year 2024 and is projected to reach a revised size of US$ 3925 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published: 2025-12-12
Pages: 121
USD 2900.00 (Single User License)Gene Cell Therapy CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-03-11
Pages: 112
USD 3950.00 (Single User License)Global Gene Cell Therapy CDMO Market Research Report 2024
The global Gene Cell Therapy CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
Published: 2024-04-28
Pages: 89
USD 2900.00 (Single User License)Gene Cell Therapy CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of %during the forecast period 2024-2030.
Published: 2024-04-28
Pages: 109
USD 3950.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4250.00
USD 6375.00
USD 8500.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now